Scientific deep-dive
GLP-1 Drugs and Alcohol Use Disorder: What the Trial Evidence Actually Shows in 2026
Semaglutide's effect on alcohol use disorder has thin trial support so far: three small randomized trials (n=48, 108, and 50). Hendershot 2025 reduced drinks per drinking day but not drinking days. Naltrexone, acamprosate, and disulfiram remain first-line.
Patient-reported and case-series accounts of semaglutide reducing alcohol cravings have made the rounds on TikTok and in the lay press for two years. The trial-level evidence is much narrower than the social-media coverage suggests. Three randomized controlled trials of semaglutide for alcohol use disorder have now been published: Hendershot et al. (JAMA Psychiatry, February 2025, n=48) [1], the 26-week SEMALCO trial in adults with obesity (Lancet, 2026, n=108) [9], and an 8-week trial of oral semaglutide (American Journal of Psychiatry, 2026, n=50) [10]. The Hendershot trial reported a statistically significant reduction in drinks per drinking day over 9 weeks but did not show a difference in the number of drinking days. There is real preclinical animal evidence and a plausible mesolimbic dopamine mechanism. There is also one earlier negative RCT of a different GLP-1 agonist (exenatide) for the same indication [2]. This article walks through the actual published evidence, the mechanism, and where semaglutide for AUD honestly stands relative to the three FDA-approved alcohol use disorder medications.
What is actually in the published literature
The trial that everyone first cited, and the earliest of the three published semaglutide RCTs in AUD, is Hendershot et al., published in JAMA Psychiatry on February 12, 2025 [1]. Here are the verified details:
- Sample size: 48 adults with alcohol use disorder (DSM-5 diagnosis), randomized 1:1 to semaglutide or placebo
- Duration: 9 weeks of active treatment
- Dose: Semaglutide 0.25 mg weekly for 4 weeks, 0.5 mg weekly for 4 weeks, then 1.0 mg for the final week, subcutaneously; the primary laboratory test was run at 0.5 mg — notably, this is lower than the 2.4 mg weight-loss dose used in STEP trials and the 1.0-2.0 mg diabetes doses used in SUSTAIN
- Setting: Outpatient laboratory protocol with a controlled alcohol self-administration session
- Primary outcome: Change in alcohol consumption during a laboratory drinking paradigm
The headline result was that semaglutide produced a statistically significant reduction in grams of alcohol consumed in the semaglutide arm versus placebo during the post-treatment laboratory self-administration session [1]. The trial also reported reductions in weekly alcohol craving and in drinks per drinking day in the semaglutide arm relative to placebo. Importantly, the trial did not demonstrate a statistically significant reduction in the number of drinking days — the effect was on intensity of drinking when drinking occurred, not on abstinence. The trial was not powered or designed to evaluate sustained abstinence as an outcome.
Two pieces of additional context matter for interpreting this result responsibly. First, with n=48 the trial is small by RCT standards and was framed by the authors themselves as a Phase 2 proof-of-concept study, not a definitive efficacy trial. Second, the doses used (0.5 mg at the primary laboratory test, 1.0 mg only in the final week) are below the typical weight-loss dose, which means the trial doesn't directly answer what the 2.4 mg Wegovy dose would do for AUD outcomes — it could be more effective, less effective, or have a different side-effect profile.
The earlier negative trial: exenatide in 2022
Before the Hendershot trial, the largest randomized GLP-1 trial in AUD was the Klausen et al. exenatide study published in JCI Insight in 2022 [2]. 127 participants with alcohol use disorder were randomized to once-weekly exenatide 2 mg (a different GLP-1 agonist) or placebo for 26 weeks, on top of cognitive behavioral therapy. The headline result was negative: exenatide did not reduce heavy drinking days compared with placebo over the 26-week trial. However, in an exploratory analysis, participants with a BMI greater than 30 showed reduced heavy drinking days and total alcohol intake on exenatide. Functional MRI showed reduced alcohol cue reactivity in the ventral striatum and septal area in the exenatide arm.
The honest summary of the human GLP-1 + AUD evidence is therefore: one negative trial of an older GLP-1 (exenatide) with a positive obese-subgroup signal, one small positive trial of semaglutide, and two semaglutide trials published in 2026. SEMALCO randomized 108 treatment-seeking adults with alcohol use disorder and obesity to semaglutide 2.4 mg or placebo for 26 weeks, on top of cognitive behavioral therapy; heavy drinking days fell 41.1 percentage points from baseline on semaglutide versus 26.4 on placebo, an estimated difference of -13.7 percentage points (95% CI -22.0 to -5.4) [9]. An 8-week trial of oral semaglutide (3 mg, then 7 mg daily) in 50 treatment-seeking adults missed its primary outcome, laboratory cue-elicited craving, and did not reduce drinks per day, but did reduce heavy drinking days [10]. Anything else you read about semaglutide and alcohol cravings is either preclinical, an observational study, a case report, or anecdote.
The preclinical animal evidence and the proposed mechanism
The preclinical case for GLP-1 agonists in addiction is substantial. Aranäs et al. (EBioMedicine, 2023) showed that semaglutide reduced alcohol intake and relapse-like drinking in both male and female rats across multiple exposure paradigms [3]. Earlier work from Vallöf and colleagues (Neuropharmacology, 2019) established that GLP-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodent models [4]. The Jerlhag (Frontiers in Pharmacology, 2023) review summarized the broader preclinical literature across multiple GLP-1 agents and multiple addictive substances [5].
The proposed mechanism is that GLP-1 receptors are expressed in the mesolimbic dopamine pathway — specifically in the ventral tegmental area and nucleus accumbens, the brain's primary reward circuit. GLP-1 receptor activation appears to attenuate dopamine release in response to addictive stimuli (alcohol, nicotine, cocaine, opioids) in animal models. If this mechanism translates to humans, you'd expect a general reward-system dampening that affects multiple substances of abuse, not just food. Opioids are one of the next places researchers are looking, with early work on GLP-1 drugs in opioid use disorder alongside buprenorphine and methadone. The Quddos et al. 2023 Scientific Reports analysis of patients with obesity on semaglutide and tirzepatide reported reduced alcohol consumption as a self-reported secondary observation [6], which is consistent with this mechanism but does not constitute trial-level evidence.
What the observational data actually shows
Beyond the randomized trials, the most-cited observational evidence comes from Wang et al. (Nature Communications, 2024) [7], a large EHR-based analysis comparing semaglutide-treated patients with controls treated with other anti-obesity or anti-diabetes medications. The study reported a reduced incidence and recurrence of alcohol use disorder diagnoses in the semaglutide arm. This is a real and intriguing signal, but it has the well-known limitations of all retrospective EHR cohort analyses: confounding by indication, residual selection bias, differential follow-up between arms, and the fundamental problem that an “AUD diagnosis” in an EHR is a proxy for what a clinician chose to document, not for actual drinking behavior. EHR cohort findings of this kind generate hypotheses; they don't establish efficacy.
The standard of care: what the FDA-approved AUD medications actually do
Semaglutide for AUD is being discussed in the context of an existing standard of care that most patients have never been offered. The Bahji et al. 2022 systematic review and network meta-analysis of pharmacotherapies for alcohol use disorder (Journal of Addiction Medicine) [8] is the best recent summary. The three FDA-approved AUD medications and their approximate effect sizes:
| Medication | FDA approved | Mechanism | Typical effect |
|---|---|---|---|
| Naltrexone (oral or injectable) | Yes | Opioid receptor antagonist; blunts the reinforcing effect of alcohol | Reduces heavy drinking days; modest effect on abstinence |
| Acamprosate | Yes | Glutamate/GABA modulation; supports abstinence post-detox | Improves abstinence rates after detoxification |
| Disulfiram | Yes | Aldehyde dehydrogenase inhibitor; produces aversive reaction with alcohol | Effective when adherence is supervised; limited otherwise |
All three are off-patent, inexpensive, and dramatically underprescribed. The Bahji meta-analysis estimated that fewer than 10% of US patients with AUD receive any FDA-approved medication for it [8]. The clinical significance of the GLP-1 + AUD story isn't that it solves a problem with no existing solution — it's that the GLP-1 mechanism (reward circuit dampening) is genuinely different from any of the three approved drugs and may help patients who don't respond to or tolerate them.
The safety questions specific to AUD patients
Patients with active heavy alcohol use are not the population in whom semaglutide has been studied. The STEP and SUSTAIN trials excluded patients with significant alcohol use, and the published AUD trials are small. A few specific safety considerations:
- Pancreatitis. Heavy alcohol use is one of the leading causes of acute and chronic pancreatitis. GLP-1 agonists carry a label warning for pancreatitis. The combination is at least theoretically additive, and the published trials are not large enough to characterize this risk.
- Hypoglycemia interaction. Alcohol blunts hepatic gluconeogenesis. GLP-1 agonists enhance insulin secretion in a glucose-dependent manner. The combination can produce more pronounced hypoglycemia than either alone, particularly in fasted or undernourished patients with chronic alcohol use.
- Nutritional status. Patients with chronic heavy alcohol use frequently have vitamin and mineral deficiencies (thiamine, folate, B12, magnesium). The gastrointestinal side effects of GLP-1 agonists can worsen oral intake and absorption, potentially deepening nutritional deficits in an already vulnerable population.
- No long-term AUD-specific data. The Hendershot trial was 9 weeks, and the longest semaglutide trial, SEMALCO, ran 26 weeks [9]. Whether the effect holds up over years of treatment is unstudied.
What this means for patients and prescribers
Honest framing for a patient asking about semaglutide for alcohol cravings in 2026:
- Semaglutide is not FDA-approved for alcohol use disorder. Any prescription for this purpose is off-label.
- The trial evidence consists of three semaglutide RCTs (n=48 for 9 weeks at low dose; n=108 for 26 weeks at 2.4 mg in people with obesity; n=50 for 8 weeks of oral semaglutide), each reporting less drinking on some outcomes but not all, and one negative trial of a different GLP-1 (exenatide).
- The mechanism is biologically plausible and the preclinical animal data is strong, but biological plausibility plus animal data is the same level of evidence that supports dozens of failed addiction drug candidates.
- The three FDA-approved AUD medications (naltrexone, acamprosate, disulfiram) are first-line, evidence-based, inexpensive, and almost universally underprescribed. If you're struggling with alcohol use, those should be discussed first with a clinician.
- For patients already taking semaglutide for weight loss who notice reduced alcohol cravings as a side effect, that observation is consistent with what the trials showed and worth telling your prescriber. It does not, however, mean that semaglutide should replace evidence-based AUD treatment.
The larger SEMALCO trial has now reported: over 26 weeks, semaglutide 2.4 mg reduced heavy drinking days more than placebo in 108 treatment-seeking adults with obesity [9]. That moves semaglutide closer to a serious case for off-label use in carefully selected patients, though SEMALCO was a single-center trial limited to people with obesity, and none of these trials compared semaglutide with naltrexone or acamprosate. The gap between “TikTok says it works” and “trial evidence supports it” has narrowed but remains wide, and any responsible editorial coverage has to make that gap clear.
For the broader picture of how semaglutide is being used (and priced) for its FDA-approved indications, see our GLP-1 pricing index and our side-effects investigation. For the cardiovascular outcomes evidence in non-diabetic adults, see our SELECT trial deep-dive. For what happens when patients stop semaglutide, see our STEP-1 / STEP-4 extension review.
Further reading
Frequently Asked Questions
References
- 1.Hendershot CS, Bremmer MP, Paladino MB, Kostantinis G, Gilmore TA, Sullivan NR, Tow AC, Dermody SS, Prince MA, Jordan R, McKee SA, Fletcher PJ, Claus ED, Klein KR. Once-Weekly Semaglutide in Adults with Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025. PMID: 39937469.
- 2.Klausen MK, Jensen ME, Møller M, Le Dous N, Jensen AME, Zeeman VA, Johannsen CF, Lee A, Thomsen GK, Macoveanu J, Fisher PM, Gillum MP, Jørgensen NR, Bergmann ML, Poulsen HE, Becker U, Holst JJ, Benveniste H, Volkow ND, Vollstädt-Klein S, Miskowiak KW, Ekstrøm CT, Knudsen GM, Vilsbøll T, Fink-Jensen A. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022. PMID: 36066977.
- 3.Aranäs C, Edvardsson CE, Shevchouk OT, Zhang Q, Witley S, Blid Sköldheden S, Zentveld L, Vallöf D, Tufvesson-Alm M, Jerlhag E. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine. 2023. PMID: 37295046.
- 4.Vallöf D, Vestlund J, Jerlhag E. Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents. Neuropharmacology. 2019. PMID: 30771711.
- 5.Jerlhag E. The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies. Frontiers in Pharmacology. 2023. PMID: 37063267.
- 6.Quddos F, Hubshman Z, Tegge A, Sane D, Marti E, Kablinger AS, Gatchalian KM, Kelly AL, DiFeliceantonio AG, Bickel WK. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Scientific Reports. 2023. PMID: 38017205.
- 7.Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nature Communications. 2024. PMID: 38806481.
- 8.Bahji A, Bach P, Danilewitz M, Crockford D, Devoe DJ, El-Guebaly N, Saitz R. Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis. Journal of Addiction Medicine. 2022. PMID: 35653782.
- 9.Klausen MK, Justesen SK, Pedersen JN, Rasmussen L, Jensen A, Jensen ME, Knorr UB, Bergmann ML, Holst JJ, Hartmann B, Koob GF, Benveniste H, Volkow ND, Ekstrøm CT, Knudsen GM, Vilsbøll T, Fink-Jensen A. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet. 2026. PMID: 42070571.
- 10.Schacht JP, Sakai JT, Raymond K, Shelton R. Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial. American Journal of Psychiatry. 2026. PMID: 42522065.
Related research
GLP-1 Drugs and Addiction Hospitalizations: What the Largest Cohorts Show
Large cohorts link GLP-1 drugs to fewer substance-related admissions and overdoses, but results shift with the comparison drug and fade after stopping. A review of the observational evidence and what it cannot show.
8 min read
2026 Obesity Medication Guidelines: ACP, Obesity Societies and VA/DoD Compared
US guidelines from 2025–2026 rank semaglutide and tirzepatide as the preferred weight-loss medicines, support long-term use and drop the 'diet first' rule. What the ACP, TOS/OMA/OAC and VA/DoD each recommend, where they differ, and what it means for coverage.
8 min read
7-Day GLP-1 Meal Plan: A Structured Framework (Not a Recipe Card)
A structured 7-day GLP-1 meal-plan framework — daily protein, fiber, and hydration targets and a cumulative habit-by-habit structure grounded in 2026 GLP-1 nutrition research, not a fabricated recipe card.
8 min read
Air Bubbles in Your GLP-1 Pen or Syringe: Do They Matter?
A small air bubble in your Ozempic, Wegovy, Mounjaro, or Zepbound pen is normal and safe. Here's why, plus when bubbles matter for compounded syringes.
6 min read
Best Exercise on a GLP-1: Strength + Cardio Plan
You don't have to exercise on a GLP-1, but resistance training protects muscle. An evidence-based weekly strength + cardio + steps plan.
9 min read
Can You Build Muscle While Losing Weight on a GLP-1?
In a GLP-1 calorie deficit, most people should aim to preserve lean mass, not build it — but beginners, returners, and higher-fat individuals can recomp.
9 min read
Where to get semaglutide (Ozempic / Wegovy) safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Oak
Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up
Read full review →From $200/mo (starting dose)
Get started →From $99/mo
Get started →From $139/mo (4-month plan rate)
Get started →